NO20063436L - Intranasal administrasjon av glukose-regulerende peptider - Google Patents

Intranasal administrasjon av glukose-regulerende peptider

Info

Publication number: NO20063436L
Authority: NO; Norway
Prior art keywords: intranasal administration; regulatory peptides; glucose regulatory; glucose; amylin
Prior art date: 2003-12-26

Application number

NO20063436A

Other languages

English (en)

Norwegian (no)

Inventor

Steven C Quay

Henry R Costantino

Original Assignee

Nastech Pharm Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-26

Filing date

2006-07-25

Publication date

2006-08-25

2006-07-25 Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co

2006-08-25 Publication of NO20063436L publication Critical patent/NO20063436L/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
239000008103 glucose Substances 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
230000001105 regulatory effect Effects 0.000 title 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 2
101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract 2
108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 2
102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 2
102100040918 Pro-glucagon Human genes 0.000 abstract 2
108010011459 Exenatide Proteins 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
108010029667 pramlintide Proteins 0.000 abstract 1
229960003611 pramlintide Drugs 0.000 abstract 1
NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Otolaryngology (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

NO20063436A 2003-12-26 2006-07-25 Intranasal administrasjon av glukose-regulerende peptider NO20063436L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53233703P	2003-12-26	2003-12-26
PCT/US2004/043312 WO2005065714A1 (en)	2003-12-26	2004-12-17	Intranasal administration of glucose-regulating peptides

Publications (1)

Publication Number	Publication Date
NO20063436L true NO20063436L (no)	2006-08-25

Family

ID=34748791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20063436A NO20063436L (no)	2003-12-26	2006-07-25	Intranasal administrasjon av glukose-regulerende peptider

Country Status (16)

Country	Link
US (1)	US20050143303A1 (de)
EP (1)	EP1696960B1 (de)
JP (1)	JP2007518722A (de)
KR (1)	KR20060134036A (de)
CN (1)	CN1933855A (de)
AT (1)	ATE480259T1 (de)
AU (1)	AU2004312043B2 (de)
CA (1)	CA2551530A1 (de)
DE (1)	DE602004029086D1 (de)
ES (1)	ES2350487T3 (de)
IL (1)	IL176541A0 (de)
MX (1)	MXPA06007317A (de)
NO (1)	NO20063436L (de)
NZ (1)	NZ548695A (de)
WO (1)	WO2005065714A1 (de)
ZA (1)	ZA200606153B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070032410A1 (en) *	2000-01-11	2007-02-08	Atossa Healthcare, Inc.	Compositions and methods for the treatment of psychiatric disorders
US20040176476A1 (en) *	2001-06-22	2004-09-09	Gyurik Robert J.	Pharmaceutical composition
US7244703B2 (en)	2001-06-22	2007-07-17	Bentley Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for peptide treatment
CA2476589C (en) *	2002-02-27	2014-02-25	Pharmain, Ltd.	Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7635463B2 (en)	2002-02-27	2009-12-22	Pharmain Corporation	Compositions for delivery of therapeutics and other materials
ES2425221T3 (es) *	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) *	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060074025A1 (en) *	2003-12-26	2006-04-06	Nastech Pharmaceutical Company Inc.	Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
WO2005112977A2 (en) *	2004-04-23	2005-12-01	Pharmain, Ltd.	Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20090069226A1 (en) *	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
WO2006009801A2 (en)	2004-06-17	2006-01-26	Valera Pharmaceuticals, Inc.	Compositions and methods for treating central precocious puberty
ES2325773T5 (es) *	2004-11-01	2014-02-24	Amylin Pharmaceuticals, Llc.	Tratamiento de la obesidad y de los trastornos relacionados
US8394765B2 (en) *	2004-11-01	2013-03-12	Amylin Pharmaceuticals Llc	Methods of treating obesity with two different anti-obesity agents
US7759312B2 (en) *	2005-03-11	2010-07-20	Endo Pharmaceuticals Solutions Inc.	Delivery of dry formulations of octreotide
NZ561400A (en) *	2005-03-11	2010-02-26	Endo Pharmaceuticals Solutions	Controlled release formulations of octreotide
AU2006288703B2 (en) *	2005-09-06	2011-09-22	Oramed Pharmaceuticals, Inc.	Methods and compositions for oral administration of proteins
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
WO2007061434A2 (en) *	2005-11-10	2007-05-31	Nastech Pharmaceutical Company Inc.	A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
EP1965828A2 (de) *	2005-12-02	2008-09-10	Nastech Pharmaceutical Company Inc.	Pharmazeutische formulierung zur erhöhten epithelialen durchlässigkeit von peptiden zur glucose-regulierung
WO2007067964A2 (en) *	2005-12-08	2007-06-14	Nastech Pharmaceutical Company Inc.	Mucosal delivery of stabilized formulations of exendin
EP2364735A3 (de)	2005-12-16	2012-04-11	Nektar Therapeutics	Verzweigte PEG-Kon jugate von GLP-1
EP1971372B1 (de)	2005-12-19	2018-11-14	PharmaIN Corporation	Trägerzusammensetzungen mit hydrophobem kern zur abgabe von therapeutischen mitteln, herstellungs- und anwendungsverfahren damit
US20090318502A1 (en) *	2006-03-22	2009-12-24	Intranasal Therapeutics, Inc.	Pharmaceutical Compositions Comprising a Hypoglycemic Agent and Methods of Using Same
WO2007146448A1 (en) *	2006-06-07	2007-12-21	Nastech Pharmaceutical Company Inc.	Pharmaceutical formulations of glp-1 derivatives
JP2010043001A (ja) *	2006-11-09	2010-02-25	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｌｐ−１誘導体とその用途
BRPI0810606B1 (pt) *	2007-04-27	2018-10-16	Endo Pharmaceuticals Solutions	dispositivo de implante e processo para sua preparação
US7960336B2 (en)	2007-08-03	2011-06-14	Pharmain Corporation	Composition for long-acting peptide analogs
US8563527B2 (en) *	2007-08-20	2013-10-22	Pharmain Corporation	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
WO2009040020A1 (en) *	2007-09-11	2009-04-02	Mondobiotech Laboratories Ag	Amylin as a therapeutic agent
US20090176892A1 (en)	2008-01-09	2009-07-09	Pharmain Corporation	Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CA3083198A1 (en) *	2008-03-26	2009-10-01	Oramed Ltd.	Methods and compositions for oral administration of proteins
CN101548961B (zh) *	2008-04-03	2011-05-04	单宝华	一种治疗糖尿病及肥胖症的口服胶囊制剂
EP2300031B1 (de) *	2008-05-05	2017-09-20	Oramed Ltd.	Verfahren und zusammensetzungen zur oralen verabreichung von exenatid
WO2009158412A2 (en)	2008-06-25	2009-12-30	Endo Pharmaceuticals Solutions Inc.	Sustained delivery of exenatide and other polypeptides
UA104866C2 (uk) *	2008-06-25	2014-03-25	Ендо Фармас'Ютікалз Солюшнз Інк.	Імплантат октреотиду, який містить вивільняючу речовину
CN108530543B (zh)	2009-02-03	2023-06-23	阿穆尼克斯制药公司	延伸重组多肽和包含该延伸重组多肽的组合物
US20100203014A1 (en) *	2009-02-04	2010-08-12	Aegis Therapeutics Llc	Zwitterionic buffered acidic peptide and protein formulations
CN101822822A (zh) *	2009-03-04	2010-09-08	北京德众万全药物技术开发有限公司	一种普兰林肽的药物组合物及其制备方法
JP5839597B2 (ja)	2009-06-08	2016-01-06	アムニクスオペレーティングインコーポレイテッド	グルコース調節ポリペプチド並びにその作成及び使用方法
CN102309453A (zh) *	2011-09-27	2012-01-11	四川大学	醋酸艾塞那肽多囊脂质体及其制备方法
ES2644962T3 (es)	2012-01-03	2017-12-01	Oramed Ltd.	Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (de)	2012-02-01	2024-04-10	Oramed Ltd.	Proteaseinhibitorhaltige zusammensetzungen, zusammensetzungen damit und verfahren zur herstellung und verwendung davon
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja)	2012-12-21	2016-03-03	サノフイ	二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
EP2941267B1 (de)	2013-01-03	2022-11-16	Oramed Ltd.	Zusammensetzungen zur verwendung in der behandlung von nafld
BR102013017626A2 (pt) *	2013-06-14	2015-02-10	Univ Rio De Janeiro	Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
CN103405753B (zh) *	2013-08-13	2016-05-11	上海仁会生物制药股份有限公司	稳定的促胰岛素分泌肽水针药物组合物
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
TW201609796A (zh)	2013-12-13	2016-03-16	賽諾菲公司	非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080150B1 (de)	2013-12-13	2018-08-01	Sanofi	Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201609799A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
CN103948544B (zh) *	2014-04-08	2016-02-17	河南农业大学	重组Exendin-4鼻腔喷雾剂及其制备方法
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
EP3117831A1 (de) *	2015-07-16	2017-01-18	Nuritas Limited	Peptide zur verwendung bei der förderung des glucosetransports in skelettmuskeln
HUE066356T2 (hu)	2017-08-24	2024-07-28	Novo Nordisk As	GLP-1 készítmények és alkalmazásaik
CN108079280B (zh) *	2017-12-30	2021-06-04	陕西慧康生物科技有限责任公司	治疗ⅱ型糖尿病的艾塞那肽滴鼻剂
CN109136176A (zh) *	2018-07-03	2019-01-04	华东师范大学	一种小鼠冻存精子复苏液复合物及其配制方法和应用
US20220273765A1 (en) *	2019-04-24	2022-09-01	Follicum Ab	Topical formulation
PE20221575A1 (es)	2020-02-18	2022-10-06	Novo Nordisk As	Formulaciones farmaceuticas
US20250127843A1 (en) *	2021-09-22	2025-04-24	Ferring B.V.	Adrenocorticotropic hormone peptide compositions and methods of use
WO2025149041A1 (zh) *	2024-01-12	2025-07-17	杭州中美华东制药有限公司	长效glp-1/gip双激动剂的鼻腔递送药物组合物
CN118001259B (zh) *	2024-02-06	2024-09-20	上海万良诚科医药科技有限公司	曲普瑞林口颊膜及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US3972995A (en) *	1975-04-14	1976-08-03	American Home Products Corporation	Dosage form
US4235871A (en) *	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
JPS5562012A (en) *	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
GB2042888B (en) *	1979-03-05	1983-09-28	Teijin Ltd	Preparation for administration to the mucosa of the oral or nasal cavity
US4259314A (en) *	1979-12-10	1981-03-31	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
JPS57110254A (en) *	1980-12-29	1982-07-09	Teijin Ltd	Coating agent of injured membrane part of oral cavity
AU8734582A (en) *	1981-06-04	1982-12-07	Pharmasol Corp., The	Dispensing system
US4501728A (en) *	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4680323A (en) *	1983-12-01	1987-07-14	Hans Lowey	Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4573996A (en) *	1984-01-03	1986-03-04	Jonergin, Inc.	Device for the administration of an active agent to the skin or mucosa
EP0159604B1 (de) *	1984-04-09	1990-11-07	Toyo Boseki Kabushiki Kaisha	Präparat mit verzögerter Freigabe zum Aufbringen auf die Schleimhäute der Mundhöhle
CA1256638A (en) *	1984-07-06	1989-06-27	Motoaki Tanaka	Polymer and its production
JP2551756B2 (ja) *	1985-05-07	1996-11-06	武田薬品工業株式会社	ポリオキシカルボン酸エステルおよびその製造法
JPH0729915B2 (ja) *	1986-02-01	1995-04-05	帝國製薬株式会社	シ−ト状口腔内貼付剤
JP2583257B2 (ja)	1986-05-05	1997-02-19	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン向性ホルモン
USRE33093E (en) *	1986-06-16	1989-10-17	Johnson & Johnson Consumer Products, Inc.	Bioadhesive extruded film for intra-oral drug delivery and process
US4837028A (en) *	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4855142A (en) *	1987-02-27	1989-08-08	Ciba-Geigy Corporation	Pharmaceutical plaster
PT88490B (pt) *	1987-09-14	1992-11-30	Novo Nordisk As	Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
US4948580A (en) *	1988-12-08	1990-08-14	E. R. Squibb & Sons, Inc.	Muco-bioadhesive composition
NL9001681A (nl) *	1990-07-24	1992-02-17	Rijksuniversiteit	Transmucosale geneesmiddelpreparaten en transmucosale toediening.
DK36492D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Praeparat
US6190894B1 (en) *	1993-03-19	2001-02-20	The Regents Of The University Of California	Method and compositions for disrupting the epithelial barrier function
US5681811A (en) *	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5424286A (en)	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JPH0859503A (ja) *	1994-08-26	1996-03-05	Teijin Ltd	ペプチド・蛋白質性薬物の経口、経粘膜投与用リポソーム製剤
US6004583A (en) *	1995-03-22	1999-12-21	Orex Pharmaceutical Development Corp.	Protein-containing polymer composition for oral administration
JPH11292787A (ja) *	1995-08-15	1999-10-26	Asahi Chem Ind Co Ltd	生理活性ペプチドを含有する経粘膜投与製剤
AU723694B2 (en) *	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
US7312196B2 (en) *	1997-01-08	2007-12-25	Amylin Pharmaceuticals, Inc.	Formulations for amylin agonist peptides
US5908825A (en) *	1997-01-09	1999-06-01	University Of Maryland At Baltimore	Dosage composition for nasal delivery and method of use of the same
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
US20030087820A1 (en) *	1999-01-14	2003-05-08	Young Andrew A.	Novel exendin agonist formulations and methods of administration thereof
US6506724B1 (en) *	1999-06-01	2003-01-14	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
US20010012829A1 (en) *	2000-01-11	2001-08-09	Keith Anderson	Transepithelial delivery GLP-1 derivatives
US6540983B1 (en) *	2000-01-25	2003-04-01	Aeropharm Technology Incorporated	Medical aerosol formulation
US20050222036A1 (en) *	2000-08-24	2005-10-06	Thomas Jefferson University	Peptide compositions with effects on blood glucose
US20030119734A1 (en) *	2001-06-28	2003-06-26	Flink James M.	Stable formulation of modified GLP-1
ATE469645T1 (de) *	2002-10-23	2010-06-15	Bristol Myers Squibb Co	Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US20040258663A1 (en) *	2003-05-08	2004-12-23	Nastech Pharmaceutical Company Inc.	Compositions and methods for enhanced mucosal delivery of interferon alpha
ES2425221T3 (es) *	2003-05-30	2013-10-14	Amylin Pharmaceuticals, Llc	Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
US20060210614A1 (en) *	2003-12-26	2006-09-21	Nastech Pharmaceutical Company Inc.	Method of treatment of a metabolic disease using intranasal administration of exendin peptide

2004
- 2004-11-18 US US10/991,597 patent/US20050143303A1/en not_active Abandoned
- 2004-12-17 AT AT04815393T patent/ATE480259T1/de not_active IP Right Cessation
- 2004-12-17 ES ES04815393T patent/ES2350487T3/es not_active Expired - Lifetime
- 2004-12-17 NZ NZ548695A patent/NZ548695A/en unknown
- 2004-12-17 CN CNA2004800421626A patent/CN1933855A/zh active Pending
- 2004-12-17 DE DE602004029086T patent/DE602004029086D1/de not_active Expired - Lifetime
- 2004-12-17 MX MXPA06007317A patent/MXPA06007317A/es active IP Right Grant
- 2004-12-17 EP EP04815393A patent/EP1696960B1/de not_active Expired - Lifetime
- 2004-12-17 CA CA002551530A patent/CA2551530A1/en not_active Abandoned
- 2004-12-17 AU AU2004312043A patent/AU2004312043B2/en not_active Ceased
- 2004-12-17 WO PCT/US2004/043312 patent/WO2005065714A1/en not_active Ceased
- 2004-12-17 JP JP2006547366A patent/JP2007518722A/ja active Pending
- 2004-12-17 KR KR1020067015029A patent/KR20060134036A/ko not_active Ceased
2006
- 2006-06-25 IL IL176541A patent/IL176541A0/en unknown
- 2006-07-25 NO NO20063436A patent/NO20063436L/no not_active Application Discontinuation
- 2006-07-25 ZA ZA200606153A patent/ZA200606153B/xx unknown

Also Published As

Publication number	Publication date
EP1696960B1 (de)	2010-09-08
ZA200606153B (en)	2007-12-27
JP2007518722A (ja)	2007-07-12
EP1696960A1 (de)	2006-09-06
AU2004312043A1 (en)	2005-07-21
WO2005065714A1 (en)	2005-07-21
ATE480259T1 (de)	2010-09-15
MXPA06007317A (es)	2007-01-26
ES2350487T3 (es)	2011-01-24
IL176541A0 (en)	2006-10-05
DE602004029086D1 (de)	2010-10-21
CA2551530A1 (en)	2005-07-21
KR20060134036A (ko)	2006-12-27
CN1933855A (zh)	2007-03-21
AU2004312043B2 (en)	2008-07-31
NZ548695A (en)	2008-04-30
US20050143303A1 (en)	2005-06-30

Legal Events

Date	Code	Title	Description
2012-07-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
IL176541A0 (en)	2006-10-05	Intranasal administration of glucose-regulating peptides
AR022368A1 (es)	2002-09-04	Procedimiento para administrar peptidos insulinotropicos
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
JOP20250198A1 (ar)	2025-08-03	مركبات مساعدة مشتركة gip/glp1
PL2070946T3 (pl)	2013-09-30	Wynalazek dotyczący GLP-1 i eksendyny
Chae et al.	2008	Preparation, characterization, and application of biotinylated and biotin− PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery
WO2003011892A3 (en)	2004-02-26	Glp-1 exendin-4 peptide analogs and uses thereof
WO2003033671A3 (en)	2005-12-29	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MX2022009149A (es)	2022-12-15	Compuestos coagonistas de gip/glp1.
NO20070614L (no)	2007-03-27	Humane glukagon-lignende-peptid-1 modulatorer og anvendelse derav ved behandling av diabetes og beslektede tilstander.
NO20071018L (no)	2007-04-11	Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
WO2004094461A3 (en)	2005-09-15	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
NZ621196A (en)	2015-08-28	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
UA97953C2 (uk)	2012-04-10	Стабілізовані поліпептиди інсуліноподібного фактора росту
WO1999043705A8 (en)	1999-10-14	N-terminally truncated glp-1 derivatives
Kim et al.	2012	Low molecular weight (1 kDa) polyethylene glycol conjugation markedly enhances the hypoglycemic effects of intranasally administered exendin-4 in type 2 diabetic db/db mice
IL146868A0 (en)	2002-08-14	A pharmaceutical composition containing an igf-i/igfbp-3 complex
Youn et al.	2008	Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
Zhang et al.	2023	Hectogram‐scale synthesis of [Aib8, Arg34]‐GLP‐1 (7–37) by liquid‐phase fragment condensation
WO2006121588A3 (en)	2007-02-15	Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
WO2005072385A3 (en)	2006-06-08	Pituitary adenylate cyclase activating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos
TW200509960A (en)	2005-03-16	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
Perušičová	2007	Inkretinová strategie léčby diabetes mellitus 2. typu-DPP-IV
CN103948544B (zh)	2016-02-17	重组Exendin-4鼻腔喷雾剂及其制备方法